Capricor Therapeutics, Inc. (CAPR)
| Previous close | 4.82 |
| Open | 5.26 |
| Bid | 5.13 x 200 |
| Ask | 5.21 x 400 |
| Day's range | 5.07 - 5.65 |
| 52-week range | 2.68 - 8.22 |
| Volume | |
| Avg. volume | 292,503 |
| Market cap | 162.871M |
| Beta (5Y monthly) | 4.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.00 |
GlobeNewswireCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
ZacksWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksHow Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
